Shustik, J. (2025). Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor. Canadian Hematology Today, 4(3), 24–35. https://doi.org/10.58931/cht.2025.4379